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Abstract: Medulloblastoma is a brain tumor that arises predominantly in infants and children. It is
the most common pediatric brain malignancy. Around 25% of medulloblastomas are driven by
constitutive activation of the Hedgehog signaling pathway. Hedgehog-driven medulloblastoma is
often studied in the laboratory using genetic mouse models with overactive Hedgehog signaling,
which recapitulate many of the pathological features of human Hedgehog-dependent tumors.
However, we show here that on a molecular level the human and mouse HH-dependent MB are quite
distinct, with human, but not mouse, tumors characterized by the presence of markers of increased
oxidative phosphorylation and mitochondrial biogenesis. The latter suggests that, unlike for many
other types of tumors, a switch to glycolytic metabolism might not be co-opted by human SHH-MB to
perpetuate their survival and growth. This needs to be taken into consideration and could potentially
be exploited in the design of therapies.
Keywords: medulloblastoma; Sonic hedgehog; Shh; oxidative phosphorylation; mitochondria;
glycolysis; Warburg effect; gene expression; mouse model
1. Introduction
Medulloblastoma (MB) is the most common pediatric brain malignancy [1]. Up to 80% of cases are
tractable with a combination of surgery and radio- and chemotherapy, but these invasive, non-targeted
approaches often leave young patients with severe neurodevelopmental deficits [2]. For these reasons,
a quest for more targeted therapies with fewer side effects is currently underway. This endeavor was
made possible thanks to the recent studies showing that MB is molecularly diverse and comprises four
distinct classes of tumors that differ in their mutation and gene expression landscape, pathological
presentation, and prognosis [1]. These classes are: SHH-MB characterized by activation of the
Hedgehog (HH) signaling pathway, WNT-MB characterized by high activity of WNT signaling,
and two molecularly distinct groups named Group 3 and Group 4, where neither HH nor WNT
signaling is activated. The SHH-MB group, comprising approximately 25% of all MB tumors, is the
best characterized of the MB classes due to the ready availability of mouse models of the disease [3].
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In recent years, inhibitors of HH signaling have emerged as some of the most promising
anti-cancer therapeutics [4,5]. These inhibitors predominantly bind to and block the activity of SMO,
a membrane protein that is the key signal transducer in the HH pathway. It was hoped that SMO
inhibitors would constitute a new weapon against MB tumors in humans. However, it turned out
that MB cells can develop resistance to SMO inhibitors [6]. Moreover, many cases of SHH-MB are
inherently independent of SMO because they are triggered by mutations downstream of SMO in the
HH pathway [7]. Consequently, SMO inhibitor drugs (Vismodegib, Erismodegib) were approved by the
FDA only for the treatment of another HH-dependent cancer, basal cell carcinoma, but not SHH-MB.
Currently, the search continues for new drugs that would be effective in treating SHH-MB.
Unfortunately, only two human SHH-MB cell lines are available commercially (DAOY, ONS-76) [8].
Thus, one of the instrumental tools for understanding the pathogenesis of human SHH-MB and
developing anti-SHH drugs are genetically-modified mouse models of SHH-MB. A number of mouse
models of SHH-MB were developed in the last two decades [3]. Included are those based on loss of the
tumor suppressor Patched [9], gain-of-function of the oncogene Smoothened [10,11], or the conditional
loss of the Gαs subunit of the heterotrimeric G proteins [12]. Despite their widely regarded utility as
tools for cancer drug discovery and testing, recent work showed that mouse models do not faithfully
reflect the molecular composition and pathological features of human SHH-MB [13].
Here, we analyze the gene expression profiles of multiple SHH-MB mouse models and compare
them to those of human SHH-MB samples. We find that human SHH-MBs, unlike tumors in mouse
models of the disease, are characterized by relatively high expression of genes associated with
mitochondrial oxidative phosphorylation. Our work suggests that therapies that target the balance
between aerobic respiration and glycolysis in tumor cells may have different outcomes in human and
mouse SHH-MB.
2. Materials and Methods
2.1. Cerebellar Granule Cell Progenitor Culture
Cerebellar granule cell progenitors (cGCPs) were isolated and cultured as described [14]. Briefly,
P3 mice were sacrificed by pentobarbital injection and decapitation. Cerebella were isolated and
digested in a trypsin/DNAse solution. cGCPs were separated by centrifugation on a 35%/60% Percoll
step gradient. They were cultured in media containing Neurobasal, penicillin/streptomycin/glutamate
(1×), 1 mM sodium pyruvate, 0.04 µg/mL triiodothyronine, 0.1 mg/mL BSA, 0.04 µg/mL sodium
selenite, 60 µg/mL N-acetylcysteine, 0.06 µg/mL progesterone, 5 µg/mL insulin, 100 µg/mL
apo-transferrin, and 16 µg/mL putrescine. For real-time RT-qPCR analysis, the cells were treated for
6 h with or without Shh-N (1 µg/mL; R&D, Minneapolis, MN, USA), PACAP-38 (10 nM; Calbiochem,
San Diego, CA, USA), or both.
2.2. Real-Time RT-qPCR
RNA was extracted using TRIzol. For cell culture, media was removed, and the TRIzol reagent
was added directly to the wells. Tissues were homogenized in TRIzol using a rotor/stator homogenizer.
RNA extraction was afterwards performed according to the TRIzol manufacturer’s protocol. cDNA
was generated using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) and quantitative
PCR was performed using the iQ SYBR green supermix (Bio-Rad). The results were analyzed using
the standard curve method with GAPDH used as the housekeeping gene. Primers used for qPCR were
as follows:
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Forward Reverse
GAPDH ggccttccgtgttcctac tgtcatcatacttggcaggtt
Gli1 atctctctttcctcctcctcc cgaggctggcatcagaa
Gpr153 ctcagagcctgccagaactt aagctcaccaccagcacag
Shisa2 ctcggcagtccccatctac cgtagacatcggcaacagc
2.3. Animal Husbandry
Mice were housed according to UCLA Institutional Guidelines, including standard light–dark
cycles with food and water ad libitum. All mice were daily monitored for signs of illness and sacrificed
when visibly unwell. WT, Ptch1 [9] and PACAP+/−/Ptch1+/− [15] mice were generated and maintained
as described previously.
2.4. In-Situ Hybridization
P6 mouse brains were surgically removed and placed into 4% paraformaldehyde for 24 h for
fixation. Adult tumor-bearing mice were transcardially perfused with 4% paraformaldehyde and
brains were postfixed in 4% paraformaldehyde for 2 h. Tissues were cryoprotected in 20% sucrose
and embedded in OCT media. Tissue was sectioned saggitally 10–12 µm and stored at −80 ◦C. In situ
hybridization with digoxygenin-labeled probes was performed as previously described [16].
Templates for ISH probe synthesis were amplified from neonatal mouse brain cDNA using PCR
and cloned into pCRII-TOPO plasmids. The probes were designed to bind region 2422-2758 of Gpr153
(NM178406.2) and region 1845-2195 of Shisa2 (NM145462.4). Both sense (S) and antisense (AS) probes
were prepared by in vitro transcription using DIG nucleic acid detection kit (Roche, Basel, Switzerland)
and tested following the manufacturer’s protocol.
Tissue sections were rehydrated in PBS with 0.1% Tween 20 and postfixed in 4% paraformaldehyde
for 10 min. Then the sections were treated with proteinase K at 37 ◦C for 3 min, postfixed again in
4% paraformaldehyde for 20 min and hybridized with digoxigenin-labeled probes against Gpr153
(600 ng/mL) and Shisa2 (300 ng/mL) overnight at 55 ◦C. After hybridization, the sections were washed
in a solution consisting of 50% formamide and 5× SSC and 1% sodium dodecyl sulfate once for 30 min
at 60 ◦C, then twice in 50% formamide and 2× SSC for 45 min at 60 ◦C and finally in Tris-buffered
saline containing 0.1% Tween 20 (TBST). The slides were then immersed in blocking solution (Roche)
and incubated overnight at 4 ◦C with anti-digoxigenin Fab-alkaline phosphatase conjugate (Roche)
diluted to 1:2000 by blocking solution. The hybrids were visualized by an alkaline phosphatase reaction
using the NBT-BCIP method (Wako, San Diego, CA, USA). The slides were then dehydrated and
coverslipped using permount.
2.5. Analysis of Medulloblastoma Gene Expression Datasets
All data analysis was done in R. For each of the datasets, the “matrix” file was downloaded from
GEO and imported into R using the getGEO function from the GEOquery library [17]. If necessary,
data were renormalized using the invariant set method (normalize.ExpressionSet.invariantset from
the affyPLM library [18]). Plots of individual expression log2 values were drawn using the beeswarm
library using the data from the probe with the maximum mean log2 expression for each gene if more
than one probe matched that gene.
For calculations involving differentiation between TP53 wild-type (WT) and TP53 mutant SHH-MB
tumors, the information regarding the mutation status of the TP53 gene was extracted from Supplemental
Table S1 from [7] and cross-referenced with tumor identifiers in the dataset GSE49243. Only data from
tumors where TP53 was sequenced was included in graphs and statistical significance calculations.
To select genes that showed the highest difference in expression between human and mouse
tumors, we applied the following procedure. First, for each probeset in each microarray dataset,
we calculated median expression value for this probeset in each of the tumor/tissue subtypes.
This generated a table with probesets in rows and tumor/tissue types in columns. In the next step,
Cells 2019, 8, 216 4 of 22
we used the collapseRows (“MaxMean” method) from the WGCNA library [19] to select the most highly
representative probeset for each gene, which resulted in a table with genes in rows and tumor/tissue
types in columns. Next, we normalized each row by subtracting the mean value for that row from all
values within the row (normalized median gene expression values). For human datasets, the columns
typically represented different subtypes of MB, whereas for mouse datasets, the columns included
normal cerebellum as controls. This generated data that allowed us to determine whether the median
expression of a gene in a specific tumor/tissue type is higher (positive values) or lower (negative
values) from other tumor/tissue types in the same dataset (tumor/tissue-dependent overexpression
values). We then ordered genes for each dataset according to their overexpression values in the
SHH-MB/Shh-MB group and calculated quantile ranks. These ranks were averaged separately
for mouse Shh-MB and human SHH-MB groups. Genes with high ranks (closer to 1) in human
tumors, but low ranks (closer to 0) in mouse tumors were considered to be human SHH-MB-specific,
and genes with low ranks in human tumors and high ranks in mouse tumors were considered to be
mouse Shh-MB-specific.
Of note, datasets containing gene expression for human samples do not contain healthy cerebellum
controls, whereas all mouse datasets do contain healthy samples as controls. To ensure that the choice of
controls does not affect analysis results, we repeated gene ranking using a recently published combined
dataset of gene expression results from healthy cerebella and different medulloblastoma subtypes
available from the GEO accession number GSE124814 [20]. The analysis was performed as follows.
For each gene and each medulloblastoma subgroup or cerebellar control, a median log-transformed
expression value was calculated. The cerebellum control medians were then subtracted from median
log expression values for each medulloblastoma subgroup, which yielded cerebellum-normalized
median log expression values, which were used for gene ranking. Similarly, for each mouse dataset,
a median log-transformed expression was calculated for each gene and each medulloblastoma
subgroup or cerebellar controls, and the cerebellum control median was subtracted from all other
groups. Cerebellum-normalized median log expression values for Shh-MB were then averaged across
mouse datasets and used for subsequent gene ranking.
Source code and raw/processed data is available upon request.
2.6. Gene Set Enrichment Analysis
To discover functional groups of genes that were either mouse Shh-MB specific or human
SHH-MB specific, genes were ordered according to the difference between ranks in human and
mouse SHH-MB tumors and the GSEApreranked tool was used [21]. The following groups of gene
sets from the MSigDB database [21] were used in the analysis: h.all.v6.2.symbols.gmt (hallmark gene
sets), c2.all.v6.2.symbols.gmt (curated gene sets), c5.all.v6.2.symbols.gmt (GO gene sets).
2.7. Immunohistochemistry
The analysis was performed on formalin-fixed paraffin embedded (FFPE) tissue samples.
Expression of COX4 protein (cytochrome c oxidase subunit 4) was detected using antibody clone
F-8 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA code: sc-376731, dilution 1:200). Antigen
retrieval was performed using Target Retrieval Solution, Low pH, (DAKO, Glostrup, Denmark) for
30 min in 99.5 ◦C. Whole preparations were scanned in Hamamatsu NanoZoomer 2.0 RS scanner
(Hamamatsu Photonics, Hamamatsu, Japan) at the original magnification 40×. p53 IHC was performed
on the Ventana BenchMark ULTRA IHC/ISH autostaining system using a mouse monoclonal antibody
(BP53-11) after antigen retrieval in CC1 buffer followed by detection with the Ultra View HRP system
(Roche/Ventana, Basel, Switzerland).
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Molecular classification of medulloblastoma samples was determined and described previously [22].
Briefly, NanoString nCounter system analysis (NanoString Technologies, Seattle, WA, USA) was
applied for identification of 4 molecular groups (WNT, SHH, Group 3, or Group 4) using a NanoString
CodeSet of 22 marker genes and 3 housekeeping genes (ACTB, GAPDH, and LDHA). Raw counts for
each gene underwent technical and biological normalization using nSolver 2.5 software (NanoString
Technologies, Seattle, WA, USA). The clustering of samples was performed with Pearson correlation
and average settings.
Four SHH tumors were determined by the presence of an immunohistochemical positive reaction
with anti-GAB1 (Abcam, #ab27439 and/or ab #59362, dilution 1:100) and anti-YAP1 (Santa Cruz
Biotechnology, #sc-101199, dilution 1:50) antibodies, as previously described [23].
3. Results
3.1. Gpr153 and Shisa2 are Shh Targets in Murine Cerebellar Granule Cell Progenitors and Mouse Shh-Type
Medulloblastoma
SHH-MB is thought to arise from cerebellar granule cell progenitors (cGCP) [24], which proliferate
extensively in the early postnatal period in a manner dependent on the Hh pathway. The proliferation
of cGCPs and SHH-MB formation is antagonized by receptors coupled to the small GTPase Gαs,
which stimulates the activity of protein kinase A and directly inhibits the Hh-dependent transcription
factors belonging to the Gli family. Consequently, the deletion of Gαs in cGCPs results in SHH-MB
formation [12]. Moreover, we previously showed that both the Shh-dependent proliferation of cGCPs
and Shh-MB tumorigenesis can be blocked by the neuropeptide PACAP (Adcyap1), one of the cerebellar
ligands of Gαs-coupled receptors. Tumors arise more quickly and with a much higher incidence
in Ptch1+/− mice that also lack a single Adcyap1 allele [14,15,25]. To identify novel biomarkers and
potential therapy targets for human SHH-MB, we previously profiled gene expression genome-wide
in cGCPs treated with Shh or co-treated with Shh and PACAP [14]. We hypothesized that genes
that responded to both physiological stimuli, i.e., were upregulated in Shh-treated cGCPs but were
downregulated by the addition of PACAP could serve as markers of Shh/Gli activity in MB precursor
cells and potential biomarkers/therapy targets for human SHH-MB. Two genes in particular were
very strongly upregulated in Shh-treated, but not Shh+PACAP-treated, cGCPs: Gpr153 and Shisa2
(Figure 1A; the full set of regulated genes is available as a supplement for reference [14]). These genes
were of particular interest to us because they encode transmembrane proteins that might be suitable as
easily accessible potential therapy targets or biomarkers. One of these genes, Gpr153, was previously
reported to be upregulated in Shh-treated cGCPs and in mouse Shh-MB and to be a direct target of
Gli1 (assessed by chromatin immunoprecipitation) [16]. Shisa2 had not been reported as a HH target
gene before and is likely not a direct Gli protein target, since blocking new protein synthesis using
cycloheximide attenuates the effects of Shh on Shisa2 expression (Figure S1).
We found that the known HH target genes Gli1 and Gpr153, as well as our newly discovered
HH target gene Shisa2, were upregulated in Shh-MB in the mouse. First, we compared the expression
of putative Shh target genes in wild-type young (postnatal day 4; P4) and adult cerebella as well
as two types of Shh-MB tumors—those derived from Ptch1+/− mice and those derived from mice
heterozygous for both Ptch1 and Adcyap1 (double heterozygous; DHz) [15]. We found that all three
putative HH target genes were expressed at higher levels in young highly proliferative cerebella
compared to adult mature cerebella. All three were also strongly upregulated in murine Shh-MB
tumors from Ptch1+/− and DHz mice (Figure 1B). These results were further confirmed using in situ
hybridization (Figure 1C,D).
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mice (D). Representative images are shown for hybridization of antisense (top) and control sense 
(bottom) probes. 
3.2. Gpr153 and Shisa2 Are Not Upregulated in Human SHH-MB. 
Based on encouraging results from the mouse model, we expected that Gpr153 and Shisa2 might 
serve as biomarkers in human SHH-MB. Because they are both transmembrane proteins, they might 
also be used as conveniently accessible drug targets in the clinic. We analyzed the expression of 
GPR153 and SHISA2 across a set of 285 human MB tumors, including 51 SHH-MB samples 
(microarray analysis results available from GEO—dataset GSE37382) [26]. Surprisingly, neither 
GPR153 nor SHISA2 expression was elevated in human SHH-MB samples compared to Group 3 and 
Group 4 tumors (WNT type tumors were not profiled in this dataset). In contrast, GLI1 was highly 
overexpressed in human SHH-MB, as expected. The lack of GPR153 and SHISA2 overexpression in 
human SHH-MB was further confirmed using another human MB gene expression dataset available 
from GEO [27] (GSE10327; Figure 2A).  
Figure 1. Shisa2 and Gpr153 are expr ssed in Shh-stimulated cer bella granule cell progenitors (cGCPs)
and murine Shh-MB. (A) Cultured cGCPs were treated for 6 h with 1µg/mL Shh-N and/or 10 nM
PACAP38. Shown is the expr ssion of indicated genes by RT-qPCR (mean +/− SD) from n = 4
independent samples/ . t i lt lt ella fro
T ice, ll cte fro Ptch1+/− and Ptch+/−; Adcyap1+/− (DHz) mice;
shown re mean +/− SD for n = 11 samples per group. (C,D) Expression of Gpr153 and Shisa2 was
measured b in s tu hybridization on samples from P4 wild-type cerebella (C) and tumors collected
from Ptch+/− mic (D). Repres nt tive images are shown f r hybrid zation of antisense (t p) a d
con r l sense (bottom) probes.
3.2. Gpr153 and Shisa2 Are Not Upregulated in Human SHH-MB
Based on encouraging results from the mouse model, we expected that Gpr153 and Shisa2 might
serve as biomarkers in human SHH-MB. Because they are both transmembrane proteins, they might
also be used as conveniently accessible drug targets in the clinic. We analyzed the expression of
GPR153 and SHISA2 across a set of 285 human MB tumors, including 51 SHH-MB samples (microarray
analysis results available from GEO—dataset GSE37382) [26]. Surprisingly, neither GPR153 nor SHISA2
expression was elevated in human SHH-MB samples compared to Group 3 and Group 4 tumors (WNT
type tumors were not profiled in this dataset). In contrast, GLI1 was highly overexpressed in human
SHH-MB, as expected. The lack of GPR153 and SHISA2 overexpression in human SHH-MB was further
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confirmed using another human MB gene expression dataset available from GEO [27] (GSE10327;
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Given this discrepancy in gene expression between human SHH-MB and mouse Shh-MB,
we wanted to know if Gpr153 and Shisa2 overexpression was a general feature of Shh subtype MBs in
mice or whether they were limited to a single model with heterozygous deletion of Ptch1. We analyzed
available datasets from multiple laboratories derived from four different models of Shh-MB: Ptch1+/−,
CAGGS-CreER; R26-SmoM2, hGFAP:GnasCKO, Oligo1:GnasCKO [12,28–30] (Table 1). Expression
of Gpr153 and Shisa2 was elevated in Shh-MB tumors independent of the genetic model used and
independent of controls (normal early postnatal cerebellar tissue/prenatal cerebellar anlage/MB
tumors from a different subgroup; Figure 2B). Thus, increased expression of Gpr153 and Shisa2 is a
characteristic feature of mouse Shh-MB tumors, but not human SHH-MBs.
Table 1. Microarray datasets used in transcriptomic analyses.
GEO Accession
Number Species Microarray Platform Ref. Dataset Description
GSE60417 mouse Affymetrix Mouse Gene 1.1 ST Array [12] Shh-MB model: Gαs cKO in Olig1- orGFAP-expressing cells
GSE9299 mouse Affymetrix Mouse Expression430A/B Array Set [29]
Shh-MB model: postnatal SmoM2
overexpression
GSE43994 mouse Illumina MouseRef-8 v2.0expression beadchip [30] Shh-MB model: Ptch1
+/−
GSE24628 mouse Affymetrix Mouse Genome 4302.0 Array [28]
Shh-MB and Wnt-MB model: Ptch1+/−;
Tp53−/− and Blbp-Cre+/−; Ctnnb1+/lox(ex3);
Tp53flx/flx
GSE37418 human Affymetrix Human Genome U133Plus 2.0 Array [31]
human tumors of different subtypes (Wnt, Shh,
Group 3, Group 4)
GSE41842 human Affymetrix Human Gene 1.0 ST Array [32] human tumors of different subtypes (Wnt, Shh,Group 3, Group 4)
GSE10327 human Affymetrix Human Genome U133Plus 2.0 Array [27]
human tumors of different subtypes (Wnt, Shh,
Group 3(C), Group 4(D), Group E)
GSE37382 human Affymetrix Human Gene 1.1 ST Array [26] human tumors of different subtypes (Wnt, Shh,Group 3)
GSE28245 human Agilent-014850 Whole HumanGenome Microarray 4x44K G4112F [33]
human tumors of different subtypes (Wnt, Shh,
Group 3, Group 4)
GSE49243 human Affymetrix Human Genome U133Plus 2.0 Array [7]
human SHH-MB tumors with matched
mutation data
3.3. Mouse Shh-MB Have Different Gene Expression Profiles from Human SHH-MB
It has been shown that human and mouse Shh-MB tumors are distinct in terms of their gene
expression profiles [13], but the conclusions of this study were based on a single microarray platform used
for each species (HGU133 plus 2.0 for human, Mouse Genome 430 2.0 form mouse). To determine whether
differences in gene expression between mouse and human Shh-MB are consistent independently
of microarray methodology, we analyzed multiple datasets from GEO that had been generated
on various microarray platforms for mouse and human (Table 1) [12,26–28,30,33]. We calculated
differences between median log-transformed gene expression values for Shh-MB and the average
median expression for all groups in each dataset. We then quantile-ranked genes that were represented
in all microarray platforms based on these differences for each dataset (Table S1). As expected, known
universal Shh target genes ranked near the top among genes upregulated in Shh-MB for all datasets,
whereas Gpr153/GPR153 only ranked near the top in mouse datasets (Figure 3A). Overall, the ranks of
Shh-MB gene expression changes were highly correlated among different human datasets and among
different mouse datasets but were less well correlated between human and mouse datasets (Figure 3B)
independently of microarray platforms and specific mouse Shh-MB models.
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Figure 3. (A) GPR153 differs in expression from canonical Shh targets in human SHH-MB. Genes from
multiple human (pink) and mouse (grey) Shh-MB datasets were ranked according to the degree to
which they are overexpressed in Shh-MB compared to other MB groups (human) or healthy cerebellar
tissue (mouse). Each point represents the quantile rank in one dataset. Boxplots show the median and
interquartile range for each gene/species pair. Canonical Shh target genes Gli1/GLI1, Ptch1/PTCH1,
Ccnd1/CCND1, and MycN/MYCN all rank highly in both mouse and human datasets, whereas Gpr153
ranks highly in all mouse datasets, but ranks in the lower half of all overexpressed genes in human
SHH-MB datasets. (B) Gene expression patterns in Shh-MB are very similar among mouse da asets
and among human datasets but show limited correlation betwe n hu an and mouse datasets.
Expression data derived from microarray analysis were downloaded from GEO and reanalyzed.
Correlogram [34] of median gene upregulation values in Shh-MB (see methods) between every two
datasets is shown. The lower panel shows concentration ellipses and loess smoothed curves; the upper
panel shows Pearson correlation coefficients in boxes shaded according to correlation coefficient values
(blue-positive, red-negative).
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3.4. Expression of HH Target Genes Is Similar Between Mouse and Human SHH-MB
The differences in gene expression profiles between SHH-MB in human disease and in mouse
models can be due to two different factors. First, the wiring of the HH pathway-dependent
transcriptome might be significantly different between human and mouse. Second, the differences may
stem primarily from differences in pathophysiology between mouse and human tumors independent of
the driving mutations in the HH pathway. If the differences result from different HH-pathway wiring,
we would expect mouse Shh-MB-upregulated genes to overlap with direct and indirect HH target
genes in the mouse, whereas human SHH-MB upregulated genes would show no such correlation
with mouse HH targets. To test this hypothesis, we compared the ranks of genes in the mouse Shh-MB
and human SHH-MB datasets with genes ranked by their coexpression with mouse Gli1 obtained
from the coxpresdb dataset [35,36]. As expected, the ranks of mouse Shh-MB-upregulated genes
showed significant correlation with the ranks of Gli1-coexpressed genes (Figure 4A). Interestingly,
genes upregulated in human SHH-MB were also enriched for genes coexpressed with mouse Gli1
(Figure 4B), suggesting that the wiring of the HH pathway transcriptome itself is similar in human
and mouse tumors. We thus conclude that the differences in gene expression profile between human
and mouse SHH-MB tumors reflect differences in tumor pathophysiology that are at least partially
independent of the HH pathway itself.
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Genes were ranked according to their likelihood of being Shh targets in the mouse based on their
coexpression patterns with the canonical Shh target Gli1 (y-axis) and ranked according to their
overexpression in mouse Shh-MB (x-axis in A) or in human SHH-MB (x-axis in B). The rank R2
value is significantly different from 0 in both cases.
3.5. Human SHH-MB, But Not Mouse Shh-MB, Have High Expression of Genes Associated with
Mitochondrial Oxidative Phosphorylation
To determine what specific features of tumor pathophysiology determines the differences between
mouse and hu an SHH-MB tumors, we ranked genes by differences between their overexpression
values between human and mouse tumors, with highest positive values for genes that were highly
upregulated in human SHH-MB tu ors but downregulated in mouse Shh-MB tumors, and lowest
negative values for genes that showed upregulation in mouse but downregulation in human SHH- B.
To determine what physiological processes were associated with the human but not mouse SHH-MB
and vice versa, this list of genes was then fed into the Gene Set Enrichment Analysis (GSEA preranked)
tool [21]. The results of GSEA point to genes associated with mitochondrial biogenesis and oxidative
phosphorylation as those that, as a group, show the highest upregulation in human SHH-MB but are
not upregulated in mouse Shh-MB (Table 2, Figure 5A,C). On the other hand, genes upregulated in
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mouse Shh-MB but not human SHH-MB are associated with active cell cycle and the Rb-E2F pathway
(Table 3, Figure 5B,D).
Table 2. Top Gene Set Enrichment Analysis (GSEA) categories for genes upregulated in human but not
mouse SHH-MB (FWER—family-wise error rate).
Gene Set Name FWER p-val
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEM
IOSMOTIC_ COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS_ 0
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT 0
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT 0
KEGG_OXIDATIVE_PHOSPHORYLATION 0
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_DN 0
MOOTHA_VOXPHOS 0
LEE_TARGETS_OF_PTCH1_AND_SUFU_DN 0
ANASTASSIOU_MULTICANCER_INVASIVENESS_SIGNATURE 0
GO_RESPIRATORY_CHAIN 0
GO_REGULATION_OF_POSTSYNAPTIC_MEMBRANE_POTENTIAL 0
LEIN_NEURON_MARKERS 0.001
VECCHI_GASTRIC_CANCER_EARLY_DN 0.001
DELYS_THYROID_CANCER_DN 0.005
GO_CELLULAR_RESPIRATION 0.007
GO_MITOCHONDRIAL_PROTEIN_COMPLEX 0.008
Table 3. Top Gene Set Enrichment Analysis (GSEA) categories for genes upregulated in mouse but not
human SHH-MB (FWER—family-wise error rate).
Gene Set Name FWER p-val
HALLMARK_E2F_TARGETS 0
REACTOME_CELL_CYCLE 0
REACTOME_CELL_CYCLE_MITOTIC 0
MARSON_BOUND_BY_E2F4_UNSTIMULATED 0
REACTOME_DNA_REPLICATION 0
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_UP 0
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP 0
ZHANG_TLX_TARGETS_60HR_DN 0
CHANG_CYCLING_GENES 0
REACTOME_S_PHASE 0
REACTOME_SYNTHESIS_OF_DNA 0
NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON 0
GO_POSTREPLICATION_REPAIR 0
KONG_E2F3_TARGETS 0.005
PUJANA_XPRSS_INT_NETWORK 0.005
FISCHER_DREAM_TARGETS 0.005
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER 0.008
Importantly, the human MB datasets available typically do not include healthy cerebellum controls.
For this reason, we used MB samples belonging to other subgroups as controls in our analysis of human
datasets. To ensure that our results are not biased by this choice of control samples, we repeated
gene ranking using a recently published dataset in which a novel statistical method was used to
combine human SHH-MB expression datasets with datasets containing expression data for healthy
human cerebella [20]. Importantly, our calculated differences in gene ranks between human and mouse
SHH-MB are mostly independent of the choice of controls (Figure S2). Moreover, when GSEA was
performed on cerebellum-normalized gene ranks, the gene sets that were enriched in human and
mouse SHH-MB samples were to a large extent similar to those obtained in our original analysis
(Tables S2 and S3). Crucially, oxidative phosphorylation-related genes were on average upregulated in
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human SHH-MB compared to human cerebella and were strongly downregulated in mouse Shh-MB
compared to mouse cerebella (Figure 5C,D and Figure S3).Cells 2019, 8, x 12 of 22 
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We then picked a few of the genes in the oxidative phosphorylation/respiratory electron transport
category for a more detailed expression analysis in selected datasets. (Figure 6). The expression of
these genes is increased in human SHH-MB tumors compared to the other subgroups and is either
decreased or unchanged in mouse Shh-MB compared to normal adult or neonatal cerebellum. Because
adult/childhood SHH-MB was found to be more similar to mouse Shh-MB models than SHH-MB in
infants [13], we hypothesized that perhaps the increased expression of mitochondrial chain genes in
human SHH-MB would only occur in infant SHH-MB, but not in the adult/childhood cases. However,
we found no consistent significant differences in expression of these genes among different age groups
of SHH-MB samples (Figure 7).
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3.6. Master Regulators of Mitochondrial Biogenesis Are Overexpressed in Human SHH-MB
One of the ways cells regulate the balance of oxidative phosphorylation vs glycolysis is via
so-called “master regulators” of mitochondrial biogenesis: PGC-1α and PGC-1β [37]. In melanoma,
PGC-1α expression is in turn controlled via the transcription factor MITF [38]. To determine whether
the MITF->PGC-1 axis may be involved in the increased expression of respiratory chain genes in
human SHH-MB, we checked the expression of genes encoding these proteins (MITF, PPARGC1A,
and PPARGC1B) in medulloblastoma transcriptomic datasets. Interestingly, all three factors are
upregulated in human SHH-MB, but their murine homologs are not upregulated in mouse Shh-MB
(Figure 8), suggesting that the increase in genes encoding respiratory chain proteins in human SHH-MB
is due to the upregulation in master regulators of oxidative phosphorylation from the PGC-1 family,
and their upstream regulator MITF.
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3.7. COX4 Is Highly Expressed in Human p53-Negative SHH-MB
To check if transcriptomic gene expression measurements are reflected in protein expression levels,
we performed immunohistochemistry on tissue sections from human MB tumors of different molecular
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subtypes resected at the Children’s Memorial Health Institute in Warsaw, Poland. In agreement
with transcriptomic data, SHH-MB tended to be strongly positive for COX4, one of the mitochondrial
respiratory chain markers, but only if the tumor was not immunoreactive for p53 (Figure 9A). Most
p53-positive tumors in the SHH subgroup had low immunoreactivity for COX4. COX4 immunoreactivity
in WNT subgroup tumors, as well as Group 3 and Group 4 tumors, was overall lower than in
p53-negative SHH-MB (Figure 9C,D). Since strong immunoreactivity for p53 is often used as a
surrogate marker for TP53 mutations [39], our data suggest that high expression of respiratory chain
components is negatively correlated with mutations in TP53 in SHH-MB tumors. Interestingly, we also
found very strong COX4 immunoreactivity in one sample of MBEN (medulloblastoma with extensive
nodularity)-type SHH-MB in the internodular region of the tumor (Figure 9B).
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To check if TP53 mutations may be associated with lower expression of oxidative 
phosphorylation genes in SHH-MB, we analyzed a gene expression dataset for SHH-MB for which 
matched genomic DNA analysis is also available [7]. Out of 73 microarray-analyzed tumor samples, 
we could find matching information on TP53 mutations on 30 of these. Twenty-five were TP53 wild-
type, and 5 had TP53 mutations, including 3 germline mutations, 1 somatic mutation, and 1 mutation 
where the origin was unknown. Although the expression of COX4I1, COX6A1, and NDUFB5 tended 
to be lower in TP53-mutated tumors (Figure 10A), the differences were not statistically significant. 
Glycolysis markers (GAPDH, HK2, PFKM), on the other hand, tended to be increased in TP53 mutant 
Figure 9. COX4 is highly expressed in a subset of human SHH-MB. Sections of FFPE tumor samples
were stained with the anti-COX4 antibody (brown) and counterstained with hematoxylin (blue).
Images were scanned at an original magnification of 40×. Digital magnification is 20× for all
images except MBEN-type SHH-MB (B). (A) COX4 in primary SHH-MB tumors according to p53
status. (B) MBEN-type SHH-MB showing strong COX4 immunoreactivity in the internodular region
imaged at 10× physical magnification. (C) WNT-MB tumors imaged at 20× physical magnification.
(D) Non-SHH-, non-WNT-type tumors imaged at 20× magnification. The molecular subgroup is
indicated for each sample.
To check if TP53 mutations may be associated with lower expression of oxidative phosphorylation
genes in SHH-MB, we analyzed a gene expression dataset for SHH-MB for which matched genomic
DNA analysis is also available [7]. Out of 73 microarray-analyzed tumor samples, we could find
matching information on TP53 mutations on 30 of these. Twenty-five were TP53 wild-type, and 5 had
TP53 mutations, including 3 germline mutations, 1 somatic mutation, and 1 mutation where the origin
was unknown. Although the expression of COX4I1, COX6A1, and NDUFB5 tended to be lower in
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TP53-mutated tumors (Figure 10A), the differences were not statistically significant. Glycolysis markers
(GAPDH, HK2, PFKM), on the other hand, tended to be increased in TP53 mutant tumors with two of
them (HK2 and PFKM) having statistically significantly higher expression in the TP53 mutant group
(Figure 10B). We are hesitant to make strong conclusions from this data due to the limited sample size,
but we believe that further analysis on a larger set of samples with matched genomic/transcriptomic
data is warranted.
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Animal models of disease constitute an indispensable step in testing novel targeted therapies 
against cancer [40]. Specifically, genetically modified mouse models of MB have been a staple among 
translational researchers developing new drugs targeting this disease. Models of SHH-MB based on 
the deletion of Ptch1 or overexpression of constitutively active Smo are relatively straightforward to 
maintain and give rise to tumors in young animals [9–11]. Despite the routine use of transgenic mice 
in testing new drugs against SHH-MB, the translation from the mouse model to treatment of human 
disease has been relatively disappointing with few notable exceptions. The major reason for the 
clinical failure of treatments developed in mouse models are profound differences between the 
heterogeneous disease in humans and its “clean” model in the murine host [13]. 
When studying both in vitro and in vivo models of SHH-MB, we discovered that the gene 
expression profile in mouse MB tumors and their human counterparts differs significantly. One major 
difference that we discovered was that human SHH-MB tumors have high expression of genes 
associated with the mitochondrial respiratory chain and oxidative phosphorylation, while mouse 
Shh-MB models do not. This was consistent across several patient cohorts and disparate studies and 
across several murine MB models. 
In addition to having reduced expression of mitochondrial genes, mouse SHH-MB also appears 
to be more highly proliferative, as suggested by elevated expression of cell cycle-associated genes. It 
is tempting to speculate that the higher proliferation rate may be associated with a drop in oxidative 
phosphorylation in mouse Shh-MB. Consistent with this hypothesis, immunohistochemical staining 
of human MB samples showed that mitochondria are abundant mostly in SHH-MB negative for p53, 
a surrogate marker of TP53 mutations [41–43]. This suggests that the more aggressive TP53 mutant 
Figure 10. Expression of markers of mitochondrial oxidative phosphorylation (A) and glycolysis (B) in
SHH-medulloblastoma (MB) tumors genotyped for mutations in the TP53 gene. Microarray data from
the GEO dataset GSE49243 was cross-referenced with supplemental data from [7] to obtain expression
data in TP53 WT and TP53 mutant subgroups. Log2 expression is shown for each subgroup for the
indicated genes.
4. Discussion
Animal models of disease constitute an indispensable step in testing novel targeted therapies
against cancer [40]. Specifically, genetically modified mouse models of MB have been a staple among
translational researchers developing new drugs targeting this disease. Models of SHH-MB based on
the deletion of Ptch1 or overexpression of constitutively active Smo are relatively straightforward to
maintain and give rise to tumors in young animals [9–11]. Despite the routine use of transgenic mice
in testing new drugs against SHH-MB, the translation from the mouse model to treatment of human
disease has been relatively disappointing with few notable exceptions. The major reason for the clinical
failure of treatments developed in mouse models are profound differences between the heterogeneous
disease in humans and its “clean” model in the murine host [13].
When studying both in vitro and in vivo models of SHH-MB, we discovered that the gene expression
profile in mouse MB tumors and their human counterparts differs significantly. One major difference that
we discovered was that human SHH-MB tumors have high expression of genes associated with the
mitochondrial respiratory chain and oxidative phosphorylation, while mouse Shh-MB models do not.
This was consistent across several patient cohorts and disparate studies and across several murine
MB models.
In addition to having reduced expression of mitochondrial genes, mouse SHH-MB also appears
to be more highly proliferative, as suggested by elevated expression of cell cycle-associated genes. It is
tempting to speculate that the higher proliferation rate may be associated with a drop in oxidative
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phosphorylation in mouse Shh-MB. Consistent with this hypothesis, immunohistochemical staining
of human MB samples showed that mitochondria are abundant mostly in SHH-MB negative for p53,
a surrogate marker of TP53 mutations [41–43]. This suggests that the more aggressive TP53 mutant
SHH-MB [44–47] shift towards more glycolytic metabolism, like the highly proliferative mouse Shh-MB
tumors. Our attempt to corroborate this data with matched genomic/transcriptomic information on
SHH-MB samples did not produce conclusive differences. While strong conclusions are not possible at
this point due to limited sample size, large variability among samples, and the inherent limitations of
semi-quantitative immunostaining methods, these results warrant further study of the relationship
between cell proliferation, oxidative phosphorylation, and TP53 status in SHH-MB. Importantly,
the negative correlation between TP53 mutations and oxidative phosphorylation has been shown
in other types of cancer [48–50], further strengthening the case for a more exhaustive investigation.
Large-scale genomic, epigenomic, and transcriptomic studies of MB are already underway and have
helped in developing more fine-grained stratification of patient cohorts [45,46]. These and similar
studies will make it possible to comprehensively test the relationship between genotype, molecular
subgroup, and metabolic state of human MB.
Our data cast some doubt on the utility of genetically-modified mouse models of SHH-MB for
preclinical studies. However, the few alternative preclinical models have their own serious drawbacks [8].
MB cell lines cultured in vitro undergo selective pressure and show evidence of phenotypic and genetic
drift [51]. Short term patient-derived cell cultures are heterogeneous and, like immortalized cell lines,
rapidly adapt to unnatural monolayer culture conditions, with non-physiological extracellular matrix,
oxygen levels, and nutrient availability. Different types of 3D cultures, either as spheroids or embedded
in ECM matrices are not in wide-spread use but are likely to be more physiologically-relevant [52].
Alternatively, patient-derived orthotopic xenografts could be used as more physiological preclinical
models, but they, too, show evidence of drift away from the original phenotype of the parent tumor [53].
A systematic characterization of different preclinical MB models is urgently needed to aid in the design
of targeted therapeutic interventions in MB [8].
An important implication of our study for the therapy of MB is that glycolytic metabolism is not as
common in human SHH-MB as it is in mouse models of the disease. Even though human MB tumors
were shown to be characterized by high uptake of 18FDG, a hallmark of aerobic glycolysis [54,55],
these studies did not take molecular subgroup into account. In the mouse, aggressive Shh-MB shows
high 18FDG uptake. Moreover, inhibition of aerobic glycolysis through genetic ablation of Hk2
markedly reduces the malignancy of these tumors [56]. This dependence of tumor cells on the Warburg
effect and aerobic glycolysis and/or lipogenesis has been suggested as a potential therapy target in
SHH-MB [57,58]. Nevertheless, data on the dependence of human SHH-MB cells on aerobic glycolysis
is lacking. Our results show that a strategy exploiting glycolytic metabolism may not be efficacious
in many human patients, but may be a good option for the more aggressive and treatment-resistant
TP53 mutant human tumors [7,44], which, like the aggressive mouse tumors, are characterized by
high expression of HK2 (Figure 10). Importantly, aerobic glycolysis and oxidative phosphorylation
may coexist in some tumors, and the high expression of mitochondrial genes does not necessarily
preclude the use of glycolytic mechanisms of energy generation. Therefore, staining for p53, COX4,
and HK2, combined with more direct assays of metabolic states such as measuring lactate production,
may help stratify patients for therapeutic intervention, especially until more exhaustive genomic and
transcriptomic diagnostics become routine in clinical practice.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/3/216/s1.
Figure S1. Upregulation of Shisa2, but not Gpr153 or Gli1, is dependent on new protein synthesis. Figure S2.
Comparison between gene rank differences (human vs. mouse) that result from analyses that use healthy
cerebellum tissues as controls (human dataset from Weishaupt et al., 2019; x-axis) and analyses that use non-SHH
MB as controls in human (y-axis). Figure S3. GSEA plots for the indicated gene sets generated from gene ranks
calculated using healthy cerebella as controls for both human and mouse datasets. Table S1. Median ranks of genes
in molecular subgroups of MB and/or cerebellar controls in different datasets. Table S2. Top GSEA categories
for genes upregulated in human but not mouse SHH-MB analyzed taking healthy cerebellar tissues as controls
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(FWER—family-wise error rate). Table S3. Top GSEA categories for genes upregulated in mouse but not human
SHH-MB analyzed taking healthy cerebellar tissues as controls (FWER–family-wise error rate).
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